“From early diagnosis, to assisting in treatment selection and response monitoring, Geneseq Biosciences believes in helping people make genomically-informed decisions across the complete cancer care path.”
Board of Directors:
Dr Ryan Van Laar received his Ph.D. in cancer genomics from the University of Melbourne (Australia). Ryan has a strong background in the translation of genomic research into robust, clinically actionable products and services. He has helped achieve CLIA, CAP and FDA clearances for several high-complexity oncology tests which have provided personalized genomic information to thousands of cancer patients worldwide.
Barton Van Laar – Co-Founder and Chairman of the Board
Barton has over 47 years’ experience in the Advertising, Marketing & Public Relations Industry. Specialised in Strategic Marketing, Business Planning, Advertising and Communications. He has an extensive record of accomplishment in affecting organisational and governmental change in addition to managing community relations. Barton has managed, advised, and invested in multiple successful early-mid stage companies across a range of sectors.
James Davison BBus CPA – Board Member
James is the Chief Financial Officer and Company Secretary of Australian Clinical Labs where he is responsible for finance, planning, reporting and governance. James’ areas of expertise include acquisitions and divestments, financial and strategic management, and operational efficiency, which were developed in a career spanning more than 17 years in the health industry. James holds a Bachelor of Business degree from Swinburne University and is a CPA.
Ingrid Winship MBChB, MD, FRACP, FACD, FAICD – Board Member
Prof Winship is a graduate of the University of Cape Town, dual trained in Clinical Genetics and Dermatology. Professor Winship is currently a member of the Victorian Cancer Agency Reference Group and a Director of the Boards of the Australasian College of Dermatologists, the Australian Genome Research Facility and Global Variome. She is Chair of the Australian Health Ethics Committee and a member of the Health Research Strategy External Advisory Group for New Zealand.
Australian Clinical Labs.
In 2018, Australian Clinical Labs and Geneseq Biosciences formed a partnership to bring the first non-invasive melanoma test to market under the trademark Melaseq™.
Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.
Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.